ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco3rd December 2019 - 11:33 am
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13–15 January 2020, at the Hilton, San Francisco Union Square.
Dr Tim Franklin, Commercial Advisor to ImmuPharma, will be presenting to conference attendees on 14th January 2020 at 10:30am (EST) in room Yosemite C (Ballroom Level). If you are attending the event and would like to meet with Dr Franklin for a one to one meeting, please contact Lisa Baderoon, Head of Investor Relations, who will be able to arrange a meeting: firstname.lastname@example.org.
Commenting on the event, Dimitri Dimitrou, CEO of ImmuPharma said: “Following on from our recent licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, the investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned. We are delighted that Dr Franklin, who was an integral part of the ImmuPharma team involved in the Avion negotiations, will be representing ImmuPharma and presenting at this prestigious Biotech Showcase. This will be a great opportunity to refocus the industry’s and investors’ minds on the significant potential within ImmuPharma’s pipeline.”Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that ImmuPharma will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. (“MAR”)